The trial included 22 patients, 18 of whom had adenocarcinoma, and reported an ORR of 18.2% (15% of cervical cancer adenocarcinomas harbor HER2 mutations) and median duration of response of 7.6 months. Here, ERBB2 is linked to adenocarcinoma.